Tournemine Simon, Bonvalot Sylvie, Mary Jean-Yves, Andreou Dimosthenis, Biau David
Université Paris-Cité, INSERM U1153, AP-HP, Hôpital Cochin, Service de Chirurgie Orthopédique, Paris, France.
Department of Surgical Oncology, Institut Curie, Paris, France.
Bone Jt Open. 2025 May 16;6(5):553-559. doi: 10.1302/2633-1462.65.BJO-2025-0026.R1.
In this study, we explore whether neoadjuvant chemotherapy influences the surgical resection strategy devised by surgeons for high-grade soft-tissue sarcoma.
A total of 12 experienced soft-tissue sarcoma surgeons rated patients who underwent neoadjuvant chemotherapy for a soft-tissue sarcoma of the thigh. Cases were randomly assigned to surgeons, such that each surgeon rated three out of the 12 cases, and each case was rated by three out of 12 surgeons (n = 36 ratings before and after chemotherapy). Surgeons were asked which surgical technique they would use: amputation; and if not, resection or dissection of critical anatomical structures in close proximity to the tumour (sciatic nerve, femoral artery, and femur). Pre- and post-chemotherapy ratings were then compared to test if chemotherapy changed the surgery aggressiveness anticipated by the surgeons.
Tumour volume increased in 9/12 cases (75%). Ratings as amputation were discordant in 5/36 cases (14%) before and after chemotherapy. The surgical technique planned by surgeons before and after chemotherapy regarding critical anatomical structures were discordant in five (14%), eight (22%), and six of 36 ratings (17%) for the sciatic nerve, the femoral artery, and the femur, respectively. Overall, a similarly aggressive surgery was planned by surgeons in nine, six, and eight cases for the sciatic nerve, the femoral artery, and the femur, respectively, which is significantly more than that expected due to chance alone. A more aggressive surgery was anticipated in five of 36 cases (14%).
Despite tumour growth being observed in 75% of cases, the surgical resection strategy devised after neoadjuvant chemotherapy remained notably similar to the one devised prior to neoadjuvant chemotherapy for critical anatomical structures. However, 'switchers', namely patients identified as being at risk of needing an amputation if the tumour experiences slight growth, should undergo conservative surgery initially, followed by chemotherapy.
在本研究中,我们探讨新辅助化疗是否会影响外科医生为高级别软组织肉瘤制定的手术切除策略。
共有12名经验丰富的软组织肉瘤外科医生对接受大腿软组织肉瘤新辅助化疗的患者进行评分。病例随机分配给外科医生,每位外科医生对12例病例中的3例进行评分,每例病例由12名外科医生中的3名进行评分(化疗前后共36次评分)。询问外科医生他们会采用哪种手术技术:截肢;如果不截肢,是否切除或解剖肿瘤附近的关键解剖结构(坐骨神经、股动脉和股骨)。然后比较化疗前后的评分,以测试化疗是否改变了外科医生预期的手术激进程度。
12例中有9例(75%)肿瘤体积增大。化疗前后,36例中有5例(14%)截肢评分不一致。化疗前后,外科医生针对关键解剖结构计划的手术技术在坐骨神经、股动脉和股骨的36次评分中分别有5次(14%)、8次(22%)和6次(17%)不一致。总体而言,外科医生分别在9例、6例和8例病例中针对坐骨神经、股动脉和股骨计划了类似激进的手术,这明显多于仅因偶然因素预期的情况。36例中有5例(14%)预期会进行更激进的手术。
尽管75%的病例观察到肿瘤生长,但新辅助化疗后制定的手术切除策略在关键解剖结构方面与新辅助化疗前制定的策略仍显著相似。然而,“转换者”,即那些如果肿瘤稍有生长就有需要截肢风险的患者,应首先接受保守手术治疗随后进行化疗。